Journal

Assess AI prescribing across identity, information, authorisation, dispensing and follow-up, rather than treating a suitable medicine as the whole decision.

Multimorbidity, frailty and personal priorities reveal where retrieving recommendations ends and individual clinical judgement must begin.

An AI answer can be medically plausible yet locally unsuitable when it imports another country's guidance, licensing assumptions or care pathways.

Medicines questions require verified patient information, product-specific sources and checked calculations, not just a persuasive AI explanation.

A transparent comparison protocol for OpenEvidence, AMBOSS and iatroX, focusing on source support, jurisdiction, uncertainty and the limits of product claims.

Understand TORTUS Health's California-first virtual care proposition, clinician approval, staged access and the evidence still needed to assess the service.

Integrated AI care may replace some standalone searches while increasing the value of inspectable evidence, recommendation review and professional learning.

Nolla Health's acne pilot raises practical questions about assessment, contraindications, follow-up and the evidence needed for safe AI prescribing.

What Nolla Health's Utah acne pilot permits, how physician oversight works, and why initial AI prescriptions are not unrestricted medical practice.

Compare official AMC and eMedici preparation, AMEDEX, CanadaQBank and iatroX for November 2026, keeping Australian context, access conditions and costs clear.

Compare official ABFM guidance, AAFP review teaching, UWorld and iatroX for November 2026, with resource choices matched to your remaining preparation needs.

Use the GPhC assessment framework to identify neglected learning, select purposeful questions and distinguish source navigation from retained understanding.